By

admin
Daniel Zerbino joins MOSAIC TX as Head of Data Science
Over the last few months, there has been a lot of activity at MOSAIC TX and we’re delighted to announce the arrival of our first team member Daniel Zerbino who is Head of Data Science. Daniel will have responsibility for leading the data science team within MOSAIC and is joining us from the European Bioinformatics...
Werner helicase colorectal cancer research
Work from the laboratory of Dr. Mathew Garnett recently identified Werner helicase as a synthetic-lethal target in cancers which are deficient in DNA mismatch repair.  During the AACR annual meeting, Dr. Garnett will present his recent findings, that help to refine our molecular understanding of Werner synthetic-lethality and demonstrating that Werner is a candidate target...
About MOSAIC We are a cancer therapeutics company using advanced computational methods and next-generation cancer models to find new synthetic-lethal cancer targets. Our main mission is to tackle cancers with substantial unmet need by reinventing target discovery. We have active programmes across a variety of cancer indications and disease biology fields and we are seeking...
organoids, Garnett lab
The forward-looking review published in the journal Nature Cancer discusses key concepts in precision cancer medicine and how synthetic-lethal genetic screens can be leveraged to identify high-value oncology targets to develop better medicines for the treatment of molecularly-defined patients.
MOSAIC Therapeutics is awarded funding from Innovate UK to use whole-genome sequencing data to identify synthetic-lethal targets in colon and oesophageal cancer. The IUK award will also be used towards company formation, the setting in place of key operations, and the formation of strategic alliances with biopharma partners.  These activities will yield MOSAIC’s first targets,...
Dr. Garnett joined a panel of distinguished speakers to discuss the use of next-generation patient-derived tumour organoids to model patient responses to therapy.  His presentation showcased the use of high-fidelity cancer models that accurately reflect patient tumours, and their application for drug efficacy testing and CRISPR genetic screens. Dr. Mathew Garnett is Co-founder and Chief...
The international symposium discusses the latest innovations in drug development and target selection. Mathew presented his use of unbiased genome-scale CRISPR genetic screens to identify and prioritise oncology targets. His work led to the discovery of Werner helicase as a synthetic-lethal target in a defined set of patients with genetic alterations leading to defects in...